Bristol-Myers Squibb

Latest Headlines

Latest Headlines

BMS racks up another Opdivo approval after FDA makes quick decision

Bristol-Myers Squibb has won yet another approval for its pioneering immuno-oncology drug Opdivo. The regulatory nod in advanced renal cell carcinoma, a form of kidney cancer, comes just one week after the FDA accepted the filing for priority review.

FDA approves BMS' Opdivo for kidney cancer a week after granting priority review

In another striking FDA turnaround for Bristol-Myers Squibb's Opdivo, the agency has approved it for treating advanced renal cell carcinoma just a week after granting priority review.

Eliquis, Opdivo push up Bristol-Myers' quarterly ad spend

Bristol-Myers Squibb spent Q3 competing in a couple of hot market races--and for that, it needed more ad dollars.

Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push

For the first time since 2013, Bristol-Myers Squibb reported a year-over-year quarterly ad spending increase. Advertising and product promotion costs rose 13% to $193 million, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. The last time ad spending was up year over year was 2013's fourth quarter.

Bristol-Myers bets $2B on Cardioxyl's heart failure therapy

Bristol-Myers Squibb is acquiring private biotech Cardioxyl Pharmaceuticals in a deal that could be worth more than $2 billion, bringing in a Phase II treatment for heart failure.

JAMA: 'Groundbreaking,' 'miracle' drugs not all they're cracked up to be in news stories

Back in September, researchers cautioned against overhyped language in FDA press releases about new meds, saying that using the terms "breakthrough" and "promising" in statements could sway individuals' expectations about a drug. Now scientists are adding more words to the wise, showing that news stories often use rosy descriptors that aren't necessarily warranted.

BMS sees sharper hep C competition in Japan in Q3

The increasingly competitive reimbursement market in Japan for leading-edge pharmaceuticals saw Bristol-Myers Squibb experience a sharp quarter-to-quarter drop in the hepatitis C segment in the third quarter.

Bristol-Myers rides Opdivo, hep C sales to Q3 beat

Bristol-Myers Squibb expects big things from its immunotherapy powerhouse Opdivo, pushing for expanded indications for the med as it competes for a top spot in the field. Now the company is celebrating the fruits of its labor, beating third quarter estimates with strong sales of its PD-1 fighter--not to mention a standout performance from its hep C franchise.

Merck's star oncology drug posts mixed results in a lung cancer trial

Merck's immuno-oncology treatment Keytruda met just one of its two goals in a late-stage lung cancer trial, a rare clinical hiccup as it works to keep pace with rival Bristol-Myers Squibb and fortify its position as more contenders move toward the market.

U.K. cost watchdog gives thumbs-up to Bristol-Myers' hep C drug

Bristol-Myers Squibb got a go-ahead from the U.K.'s cost gatekeeper for its chronic hep C med Daklinza (daclatasvir), a win for the company as it competes with Gilead Sciences and AbbVie in a fiercely contentious hep C market.